p53 Review Article

You have free access to this content

TP53 and ovarian cancer†

  1. Monique Schuijer,
  2. Els M.J.J. Berns*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10181

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 285–291, March 2003

Additional Information

How to Cite

Schuijer, M. and Berns, E. M.J.J. (2003), TP53 and ovarian cancer. Hum. Mutat., 21: 285–291. doi: 10.1002/humu.10181

Author Information

  1. Erasmus MC, Department of Medical Oncology, Rotterdam, The Netherlands

*Erasmus MC, Josephine Nefkens Institute, Room Be 424, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands

  1. †

    for the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (127K)

Keywords:

  • cancer;
  • ovarian cancer;
  • TP53;
  • histology;
  • prognosis;
  • BRCA1;
  • DPH2L1;
  • OVCA1;
  • OVCA2;
  • tumor suppressor

Abstract

Ovarian cancer represents the fourth most frequent type of cancer among females and is the leading cause of death from gynecological cancer in the western world. This review describes gene alterations in ovarian cancer. Specific emphasis is placed on genetic alterations and the prevalence of TP53 (p53) gene alterations in the distinct biological ovarian tumors (benign, borderline, and malignant) and histological subtypes (serous, mucinous, endometrioid, clear cell), as well as in BRCA1-associated hereditary ovarian cancer. Although multi-modality treatment regimens, including cytoreductive surgery and cisplatin-containing combination chemotherapy, have usefully prolonged survival, the overall cure rate of the disease has not changed dramatically. Ovarian cancer is difficult to eradicate completely by surgery and many patients have only a partial response to postoperative chemotherapy and/or many will develop chemotherapy resistance. All these important factors contribute to the poor prognosis of ovarian cancer patients. In this review, the putative prognostic or predictive value of TP53 in ovarian cancer is addressed. Hum Mutat 21:285–291, 2003. © 2003 Wiley-Liss, Inc.

Get PDF (127K)